Teplizumab is the UK’s first-ever approved medicine that can be used treat type 1 diabetes using immunotherapy - which activates or suppresses the body’s immune system. Teplizumab has been approved for by MHRA for people with Stage 2 T1D, which is an earlier stage where people are at high risk of progressing to Stage 3 T1D.
This is a companion discussion topic for the original article at https://patient.info/news-and-features/mhra-approves-teplizumab-to-delay-progression-of-type-1-diabetes